MYASTHENIA GRAVIS

 

Myasthenia gravis (MG) occurs when communication between nerves and muscles is impaired due to antibodies attacking the neuromuscular junction, where nerve impulses are transmitted to muscles.

Key features of myasthenia gravis include:

1.  Muscle Weakness: The hallmark symptom is muscle weakness that worsens with activity and improves with rest. This weakness can affect various muscles, including those controlling eye movement, facial expressions, chewing, swallowing, and speaking, as well as muscles in the limbs.

2.  Fatigue: Fatigue sets in quickly with muscle use, leading to difficulty sustaining activities for extended periods.

3.  Ocular Symptoms: Around two-thirds of individuals with myasthenia gravis experience initial symptoms limited to the muscles controlling eye movement, leading to double vision (diplopia), drooping eyelids (ptosis), or both.

4.  Bulbar Symptoms: Weakness in muscles involved in speech (dysarthria) and swallowing (dysphagia) can occur, leading to difficulties in speaking and eating.

5.  Generalized Weakness: In more severe cases, weakness can spread to involve muscles of the limbs, neck, and respiratory system, potentially leading to respiratory compromise.

6.  Variable Symptoms: Symptoms can vary widely among individuals and may fluctuate in severity over time.

7.  Trigger Factors: Certain factors such as stress, illness, fatigue, or medication may exacerbate symptoms.

Diagnosis typically involves a combination of clinical evaluation, blood tests to detect specific antibodies, neurophysiological studies (such as electromyography), and sometimes imaging studies like CT scans or MRI to rule out other conditions.

Treatment aims to improve muscle strength and reduce symptoms. Common treatment options include:

• Medications: Acetylcholinesterase inhibitors, such as pyridostigmine, can improve muscle strength by increasing the levels of acetylcholine, a neurotransmitter involved in muscle contraction.
• Immunosuppressive Therapy: Medications like corticosteroids, azathioprine, or mycophenolate mofetil may be used to suppress the immune system and reduce antibody production.
• Plasma Exchange (Plasmapheresis): This procedure involves removing antibodies from the blood plasma and replacing it with antibody-free plasma.
• Intravenous Immunoglobulin (IVIG): IVIG infusions can provide temporary relief by supplying the body with healthy antibodies to block the action of the harmful ones.
• Thymectomy: Surgical removal of the thymus gland is sometimes recommended, particularly in younger patients or those with thymoma (a tumor of the thymus gland).

Management of myasthenia gravis often requires a multidisciplinary approach involving neurologists, immunologists, and other healthcare professionals to tailor treatment to each individual's needs and monitor for potential complications. With proper management, many individuals with myasthenia gravis can lead fulfilling lives.

Top of Form

Bottom of Form